A5036495661- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Multiple Myeloma Research and Treatments
- Kruppel-like factors research
- Chronic Lymphocytic Leukemia Research
- Renal Diseases and Glomerulopathies
- Inflammatory Biomarkers in Disease Prognosis
- Hematopoietic Stem Cell Transplantation
- Lymphoma Diagnosis and Treatment
- Cell Adhesion Molecules Research
- Eosinophilic Disorders and Syndromes
- T-cell and Retrovirus Studies
- Cancer Risks and Factors
- Sphingolipid Metabolism and Signaling
- Radiomics and Machine Learning in Medical Imaging
- Acute Myeloid Leukemia Research
- Pancreatic function and diabetes
- Acute Lymphoblastic Leukemia research
- Complement system in diseases
- NF-κB Signaling Pathways
- Hematological disorders and diagnostics
- Chronic Myeloid Leukemia Treatments
- Blood groups and transfusion
- Viral-associated cancers and disorders
- Hemoglobinopathies and Related Disorders
Haydarpaşa Numune Eğitim ve Araştırma Hastanesi
2023-2024
Bahçeşehir University
2024
Sağlık Bilimleri Üniversitesi
2023
Marmara University
2019-2022
Palmetto Hematology Oncology
2019
Purpose: We aimed to study the inflammatory parameters of complete blood count in breast cancer cases. Materials and Methods: This retrospective covered 178 patients 107 age body mass index matched healthy women. Complete parameters, neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte (PLR) MPV/platelet were analyzed. Results: The leukocyte, neutrophil higher patient group (p values 0.001, 0.0001 0.0001, respectively) while haemoglobin hematocrit control (p=0.0001 for both). Logistic...
Objective: In this study, we investigated the effects of calreticulin (CALR) and JAK2V617F mutational status on clinical course disease outcomes in Turkish patients with essential thrombocythemia (ET). Materials Methods:Seventeen centers from Türkiye participated study CALR-and JAK2V617F-mutated ET were evaluated retrospectively.Results: A total 302 included, whom 203 (67.2%) 99 (32.8%) JAK2V617F-and CALR-positive, respectively.CALR-mutated significantly younger (51 years vs. 57.5 years,...
Peripheral blood-derived hematopoietic stem cells (HSCs) are widely used for various adult cell transplants. To obtain sufficient HSCs from healthy volunteer donors during the apheresis process and ensure that exposed to fewer apheresis-related side effects, calculation methods have been developed prediction of processed blood volume or CD34+ count. However, there is no consensus on a formula predict be number obtained.
In this retrospective cohort of patients with primary, post-polycythemia vera, or post-essential thrombocythemia myelofibrosis, 57 MF who received ruxolitinib for MF-related symptoms symptomatic splenomegaly were evaluated.The median age the in was approximately 58 years. Of these, there 33 (57.9%) INT-1, 23 (40.4%) INT-2, and 1 patient (1.8%) at high risk. Overall, spleen size reduction least 35% (spleen response) achieved 56.6% 63.3% all INT-1 risk any time, respectively.Symptom response...
Background: Nilotinib is an effective treatment option for patient's refractory or intolerant to imatinib and can be given as 2nd 3rd line in Turkey. Aims: In this retrospective study, we aim demonstrate the frequency of side effects patients on Nilotinib. Methods: We analyzed 253 with chronic myeloid leukemia (CML) followed by Marmara University Hematology Department. 53 these (%20.9) were a period their treatment. Clinical characteristics are table 1. Results: Median duration before...
Topic: 14. Myeloma and other monoclonal gammopathies - Clinical Background: Extramedullary disease (EMD) is defined as a soft tissue involvement resulting from hematogenous spread or tumor mass adjacent to bones arising focal skeletal lesions in patients with multiple myeloma (MM). Although the survival of EMD considered be poor, it may vary depending on site, stage involvement, well response therapy. Aims: There are few studies literature which evaluate factors affecting EMD. The aims this...
Searchable abstracts of presentations at key conferences in endocrinology ISSN 1470-3947 (print) | 1479-6848 (online)
Background: Myelofibrosis (MF) is a myeloproliferative disease that characterized by variable life expectancy, cytopenia, splenomegaly, and constitutional symptoms. Although allogeneic stem cell transplantation can be curative treatment, it carries high risk of morbidity mortality (1,2). Ruxolitinib, JAK2 inhibitor, new treatment option which improves symptomatic splenomegaly in patients with intermediate myelofibrosis. Aims: In this retrospective study we documented our real clinical...
Background: Multiple Myeloma (MM) is a hematological malignancy in which renal involvement common. Almost half of MM patients have increased creatinine levels at the time diagnosis. In 20% these patients, level above 2 mg/dl. Kidney damage can be reversible 50% patients. Aims: this retrospective study, we evaluated outcomes autologous stem cell transplantation (ASCT) was done our center multiple myeloma with failure. We compared normal functions and who underwent ASCT. failure, melphalan 140...